Skip to main content
. 2022 Apr 25;8:227. doi: 10.1038/s41420-022-00949-y

Fig. 4. MDM2 degrades p53 through ubiquitination and promotes the expression of IL5RA.

Fig. 4

A The expression of p53 in normal uveal epithelial cells ARPE-19, uveal melanoma cells MUM-2B, and drug-resistant cell line MUM-2B/CDDP as determined by RT-qPCR. B The expression of p53 in MUM-2B/CDDP cells upon JMJD2C silencing and MUM-2B cells upon JMJD2C overexpression as measured by Western blot assay. C The expression of p53 in MUM-2B cells upon MDM2 overexpression as measured by Western blot assay. D The stability of p53 protein after CHX treatment. E The expression of IL5RA in uveal melanoma tissues as determined by RT-qPCR (uveal melanoma = 32, normal = 30). F The expression of IL5RA in normal uveal epithelial cells ARPE-19, uveal melanoma cells MUM-2B and drug-resistant cell line MUM-2B/CDDP as determined by RT-qPCR. G IL5RA expression in MUM-2B/CDDP cells upon p53 overexpression and MUM-2B cells upon p53 silencing measured by Western blot assay. H The enrichment of p53 in the IL5RA promoter region in MUM-2B/CDDP cells and MUM-2B cells analyzed by ChIP. I The expression of MDM2, p53, and IL5RA in MUM-2B cells treated with oe-MDM2 or combined with oe-p53 as measured by Western blot assay. * p < 0.05. Cell experiments were repeated three times independently.